{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:13:10Z","timestamp":1790856790189,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.028","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T18:08:48Z","timestamp":1576865328000},"page":"1746-1752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999\u20132017"],"prefix":"10.1016","volume":"38","author":[{"given":"John R.","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penina","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige L.","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-2935","authenticated-orcid":false,"given":"Gra\u00e7a M.","family":"Dores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-1502","authenticated-orcid":false,"given":"Silvia","family":"Perez-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.028_b0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.clindermatol.2014.12.009","article-title":"Cutaneous reactions to vaccinations","volume":"33","author":"Rosenblatt","year":"2015","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0010","unstructured":"World Health Organization. Vaccine Safety Basics e-learning course, Module 3: Adverse events following immunization. Available at: http:\/\/vaccine-safety-training.org\/vaccine-reactions.html."},{"key":"10.1016\/j.vaccine.2019.12.028_b0015","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00006454-200012000-00002","article-title":"Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up","volume":"19","author":"Patja","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.12.028_b0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/cod.12053","article-title":"Unexpected loss of contact allergy to aluminium induced by vaccine","volume":"68","author":"Gente Lidholm","year":"2013","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.vaccine.2019.12.028_b0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1468-3083.2004.00989.x","article-title":"Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare","volume":"18","author":"Criado","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/PEC.0000000000000840","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review","volume":"32","author":"Alerhand","year":"2016","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.vaccine.2019.12.028_b0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006454-200102000-00022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system","volume":"20","author":"Ball","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.12.028_b0050","unstructured":"Centers for Disease Control and Prevention. U.S. Vaccines: Table 1. Available at: http:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/appendices\/B\/us-vaccines.pdf. Accessed September 26, 2018 2018."},{"key":"10.1016\/j.vaccine.2019.12.028_b0055","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.028_b0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.12.028_b0065","unstructured":"MEDDRA. Available at: www.meddra.com."},{"key":"10.1016\/j.vaccine.2019.12.028_b0070","unstructured":"Government Publication Office. Electronic Code of Federal Regulations. Available at: https:\/\/www.ecfr.gov\/cgi-bin\/text-idx?SID=9204d57c02b340d41b55e5b26fcfb00c&mc=true&node=se21.7.600_180&rgn=div8 Accessed 16 Jul 2019 2019."},{"key":"10.1016\/j.vaccine.2019.12.028_b0075","doi-asserted-by":"crossref","unstructured":"Robinson CL, Romero JR, Kempe A, Pellegrini C. Advisory Committee on Immunization Practices Child\/Adolescent Immunization Work G. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. MMWR Morb Mortal Wkly Rep 2017;66:134\u20135.","DOI":"10.15585\/mmwr.mm6605e1"},{"key":"10.1016\/j.vaccine.2019.12.028_b0080","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jid.2017.05.010","article-title":"Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort","volume":"137","author":"Gillis","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0085","unstructured":"Food and Drug Administration. Vaccines Licensed for Use in the United States. 2018. Available at: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm093833.htm. Accessed January 10, 2019."},{"key":"10.1016\/j.vaccine.2019.12.028_b0090","unstructured":"Centers for Disease Control and Prevention. CDC Wonder: Bridged-Race Population Estimates 2017. Available at: https:\/\/wonder.cdc.gov\/bridged-race-population.html. Accessed January 10, 2019 2019."},{"key":"10.1016\/j.vaccine.2019.12.028_b0095","unstructured":"Centers for Disease Control and Prevention. Influenza Vaccination Coverage: FluVaxView. 2017. Available at: https:\/\/www.cdc.gov\/flu\/fluvaxview\/index.htm. Accessed January 10; 2019."},{"key":"10.1016\/j.vaccine.2019.12.028_b0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2019.12.028_b0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2019.12.028_b0110","unstructured":"Centers for Disease Control and Prevention. About The Vaccine Adverse Event Reporting System (VAERS) Available at: https:\/\/wonder.cdc.gov\/vaers.html."},{"key":"10.1016\/j.vaccine.2019.12.028_b0115","unstructured":"Food and Drug Administration. Heplisav-B. Available at: https:\/\/www.fda.gov\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm584752.htm. Accessed 4 March 2019."},{"key":"10.1016\/j.vaccine.2019.12.028_b0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.12.028_b0125","doi-asserted-by":"crossref","unstructured":"Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. Dermatol Online J 2018;24.","DOI":"10.5070\/D3241037941"},{"key":"10.1016\/j.vaccine.2019.12.028_b0130","doi-asserted-by":"crossref","first-page":"274","DOI":"10.18176\/jiaci.0169","article-title":"Stevens-Johnson syndrome after influenza vaccine injection","volume":"27","author":"Oda","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00000372-199704000-00005","article-title":"Erythema multiforme and toxic epidermal necrolysis: a comparative study","volume":"19","author":"Paquet","year":"1997","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0145","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jocn.2015.01.016","article-title":"Lamotrigine-induced severe cutaneous adverse reaction: update data from 1999\u20132014","volume":"22","author":"Wang","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.vaccine.2019.12.028_b0150","first-page":"49","article-title":"Demography of the UK adverse reactions register of spontaneous reports","volume":"16","author":"Speirs","year":"1984","journal-title":"Health Trends"},{"key":"10.1016\/j.vaccine.2019.12.028_b0155","doi-asserted-by":"crossref","unstructured":"Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB, Advisory Committee on Immunization P. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017. Ann Intern Med 2017;166:209\u201319.","DOI":"10.7326\/M16-2936"},{"key":"10.1016\/j.vaccine.2019.12.028_b0160","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/13543784.17.4.555","article-title":"ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine","volume":"17","author":"Greenberg","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.vaccine.2019.12.028_b0165","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15585\/mmwr.mm6510a2","article-title":"Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses - recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015","volume":"65","author":"Petersen","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.12.028_b0170","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/14760584.2016.1175305","article-title":"Defending against smallpox: a focus on vaccines","volume":"15","author":"Voigt","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.12.028_b0175","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1001\/jama.289.24.3295","article-title":"Response to smallpox vaccine in persons immunized in the distant past","volume":"289","author":"Frey","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.12.028_b0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000254898","article-title":"Erythema multiforme following vaccination for human papillomavirus","volume":"220","author":"Katoulis","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.vaccine.2019.12.028_b0185","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/jama.1994.03510440062034","article-title":"Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine","volume":"271","author":"Stratton","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.12.028_b0190","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1093\/jpids\/piw085","article-title":"Characterization of Children With Recurrent Episodes of Stevens Johnson Syndrome","volume":"6","author":"Olson","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2019.12.028_b0195","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1542\/peds.2015-0278","article-title":"Outbreak of Mycoplasma pneumoniae-associated Stevens-Johnson Syndrome","volume":"136","author":"Olson","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.12.028_b0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0190-9622(88)70027-4","article-title":"Acyclovir for recurrent erythema multiforme caused by herpes simplex","volume":"18","author":"Huff","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0205","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2340\/00015555-2569","article-title":"Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics","volume":"97","author":"Siedner-Weintraub","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0210","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/pde.13370","article-title":"Influenza B virus infection and Stevens-Johnson syndrome","volume":"35","author":"Tamez","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0215","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.vaccine.2019.12.028_b0220","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217255","article-title":"Case of Steven-Johnson Syndrome in a male with breast cancer secondary to docetaxel\/cyclophosphamide therapy","author":"Jarrett","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.vaccine.2019.12.028_b0225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/ckj\/sfu027","article-title":"Cyclophosphamide-induced toxic epidermal necrolysis: vigilance needed","volume":"7","author":"Patel","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.vaccine.2019.12.028_b0230","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.vaccine.2014.03.063","article-title":"Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine","volume":"32","author":"Daley","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.028_b0235","doi-asserted-by":"crossref","first-page":"e68231","DOI":"10.1371\/journal.pone.0068231","article-title":"Stevens-johnson syndrome associated with drugs and vaccines in children: a case-control study","volume":"8","author":"Raucci","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.028_b0240","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-4632.2006.02953.x","article-title":"Benign hypersensitivity reactions to smallpox vaccine","volume":"46","author":"Bessinger","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.vaccine.2019.12.028_b0245","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.028_b0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/adc.83.4.347","article-title":"Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome","volume":"83","author":"Leaute-Labreze","year":"2000","journal-title":"Arch Dis Child"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:40:56Z","timestamp":1759401656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316706"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999\u20132017","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}